Table 2 Main characteristics of patients by treatment group (efavirenz vs. protease inhibitors)
| Â | On efavirenz (n: 24) | On protease inhibitors (n: 78) | p value |
|---|---|---|---|
Gender | Â | Â | Â |
   male (n: 64, 63%) | 14/24, 58% | 50/78, 64% | 0.609 |
   female (n: 38, 37%) | 10/24, 42% | 28/78, 36% |  |
Age (years) | Â | Â | Â |
   ≥ 50 (n: 27, 26%) | 9/24, 37% | 18/78, 23% | 0.161 |
   < 50 (n: 75, 74%) | 15/24, 62% | 60/78, 77% |  |
Nationality | Â | Â | Â |
   Italy (n: 83, 81%) | 19/24, 79% | 64/78, 82% | 0.751 |
   Other countries (n: 19, 19%) | 5/24, 21% | 14/78, 18% |  |
Transmission | Â | Â | Â |
   Heterosexual (n: 73, 72%) | 19/24, 79% | 54/78, 69% | 0.269 |
   men who have sex with men (n: 24, 23%) | 3/24, 12% | 21/78, 27% |  |
   IVDU/infected blood (n: 5, 5%) | 2/24, 8% | 3/78, 4% |  |
HIV clinical stage | Â | Â | Â |
   AIDS (n: 43, 42%) | 8/24, 33% | 35/78, 45% | 0.317 |
   non-AIDS (n: 59, 58%) | 16/24, 67% | 43/78, 55% |  |
Hepatitis virus coinfections | Â | Â | Â |
   No (n: 93, 91%) | 20/24, 83% | 73/78, 94% | 0.121 |
   Yes (n: 9, 9%) | 4/24, 17% | 5/78, 6% |  |
Baseline CD4+ T cells/μL |  |  |  |
   < 100/μL (n: 48, 47%) | 8/24, 33% | 40/78, 51% | 0.123 |
   ≥ 100/μL (n: 54, 53%) | 16/24, 67% | 38/78, 49% |  |
Baseline HIV-RNA (copies/mL, log 10 ) | Â | Â | Â |
   < 5 log10/mL (n: 26, 25%) | 8/24, 33% | 18/78, 23% | 0.313 |
   ≥ 5 log10/mL (n: 76, 74% | 16/24, 67% | 60/78, 77% |  |